Simone Silva Steiner De Luca | Chief Technical Officer
Transgene

Simone Steiner joined Transgene in April 2025 as Chief of Technology Officer.

Simone Steiner, PhD, is a Senior Executive and Board Advisor with almost 20 years of pharma experience across preclinical, clinical and commercialization gained within organizations ranging from startups to multinational Pharma companies.

Prior to joining Transgene, she was the Chief Technical Operating Officer (CTOO) at T-knife Therapeutics, a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, where she led technical development and manufacturing.

Before her time at T-knife, Dr. Steiner was Head of Technical Development and Manufacturing at Tigen, in Switzerland, where she managed the optimization of manufacturing processes and the creation of new biopharmaceutical products.

Dr. Steiner’s career also includes over ten years at Novartis, where she expanded her expertise in technical operations and manufacturing, contributing to large-scale production strategies for groundbreaking therapies.

With a strong foundation in cutting-edge technologies and their implications for health, Dr. Steiner is recognized for combining scientific precision with strategic management to advance therapeutic development and manufacturing initiatives.

She served as a Scientific Advisor at NegotiumAI, an innovative platform leveraging state-of-the-art AI to streamline the relationship between advanced therapy drug developers and contract manufacturers.
 
Dr. Steiner holds a Master’s in Biochemistry, a PhD from ETH Zurich and completed a postdoctoral fellowship at the University of Alberta, Canada.